<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Milltrust Ventures ]]></title><description><![CDATA[Milltrust Ventures ]]></description><link>https://www.milltrust.vc/blog</link><generator>RSS for Node</generator><lastBuildDate>Mon, 03 Aug 2026 21:43:37 GMT</lastBuildDate><atom:link href="https://www.milltrust.vc/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Roslin Technologies is now an EIT Food RisingFoodStars 2026 Verified Scaleup ]]></title><description><![CDATA[Roslin Technologies’ recognition as an EIT Food RisingFoodStars 2026 Verified Scaleup is an encouraging milestone and a strong example of why patient, early-stage capital matters. One of Milltrust’s longstanding priorities has been to support science-led companies from their earliest stages. In 2016, Milltrust backed Roslin Technologies through a £10 million seed investment, which became one of the first investments of the British Innovation Fund. The fund was established to invest in...]]></description><link>https://www.milltrust.vc/post/roslin-technologies-is-now-an-eit-food-risingfoodstars-2026-verified-scaleup</link><guid isPermaLink="false">6a62e736424f5a9980a6d0ed</guid><category><![CDATA[News]]></category><pubDate>Wed, 22 Jul 2026 18:30:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/86c0bd_bcf0e7adb5894054b9ead40d8f42da18~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Milltrust International</dc:creator></item><item><title><![CDATA[Jiva.AI and Aevice Health partner to pioneer breakthrough medical AI for Asthma adverse event prediction using AeviceMD]]></title><description><![CDATA[Jiva.AI and Aevice Health develop AI model to predict asthma attacks up to 72 hours in advance For the more than 545 million people living with chronic respiratory disease worldwide, an asthma attack can arrive without warning — a sudden deterioration that, caught late, ends in an emergency room. Jiva.AI and Aevice Health have spent three years working to change that, completing a joint programme that produced an AI model capable of predicting asthma exacerbations within 24, 48, and 72-hour...]]></description><link>https://www.milltrust.vc/post/jiva-ai-and-aevice-health-partner-to-pioneer-breakthrough-medical-ai-for-asthma-adverse-event-predic</link><guid isPermaLink="false">6a438ebc51416e35e785a03e</guid><pubDate>Tue, 30 Jun 2026 09:40:26 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/86c0bd_6d70b62ce9634029b3a88b354f5c126d~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Milltrust International</dc:creator></item><item><title><![CDATA[Strategic partnership struck between Attomarker and EpitogenX]]></title><description><![CDATA[Attomarker, a spinout from the University of Exeter, has signed a co-development agreement with EpitogenX to advance precision immunology diagnostics across multiple diseases, starting from Lyme Disease and Long Lyme. This partnership helps to unite both companies’ complementary strengths in next-generation antigen engineering and multiplex immunological diagnostics. The objective is to accelerate the development and commercialisation of a new class of precision diagnostics built on...]]></description><link>https://www.milltrust.vc/post/strategic-partnership-struck-between-attomarker-and-epitogenx</link><guid isPermaLink="false">69e1f8ff6d0f12022d45752d</guid><pubDate>Mon, 16 Feb 2026 18:30:00 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_67dcb9ec551447628a1956656feb8872~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Milltrust International</dc:creator></item><item><title><![CDATA[Curie Oncology partners up with Oncoshot to deploy AI in improving patient outcomes in Asia, makes strategic investment into the company]]></title><description><![CDATA[Curie Oncology, one of Southeast Asia’s fastest growing private oncology networks that runs numerous clinical trials across Singapore and Malaysia, has partnered with Singapore-based healthtech company Oncoshot to deploy AI-powered clinical research tools that can rapidly structure and analyse clinical data, enabling oncologists and research teams to identify eligible patients sooner and help patients gain faster access to ongoing clinical trials more efficiently.   AI as an enabler...]]></description><link>https://www.milltrust.vc/post/curie-oncology-partners-up-with-oncoshot-to-deploy-ai-in-improving-patient-outcomes-in-asia-makes-s</link><guid isPermaLink="false">69e1f8ff6d0f12022d45752e</guid><pubDate>Mon, 15 Dec 2025 10:03:50 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_ef41e1a138814b7d9c214b83707904e4~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Milltrust International</dc:creator></item></channel></rss>